옵션 체인은 다양한 행사가격과 만기일에 대한 Cytokinetics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Cytokinetics에 대한 시장 심리를 평가합니다..

Cytokinetics (NASDAQ:CYTK) 주식, 옵션 체인

CYTOKINETICS INC

Cytokinetics

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

News

Price Target

Reiteration

Analyst Ratings

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

Citizens Capital Markets analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

Citizens Capital Markets Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

U.S. stocks were lower, with the Dow Jones index falling over 100 points on Wednesday.
Shares of Cognyte Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) rose sharply during Wednesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/CGNT">fourth-quarter financial results</a>.
Cognyte Software posted adjusted earnings of 3 cents per share, beating market estimates of 1 cent per share. The company's quarterly sales came in at $94.505 million versus expectations of $93.154 million.
Cognyte Software shares jumped 22.1% to $10.04 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares rose 13.7% to $10.98 after the company reported better-than-expected third-quarter sales results and raised its FY25 guidance above estimates.</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) gained 13.1% to $14.26.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares rose 12% to $41.99.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) shares surged 11.7% to $10.69.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 10.1% to $57.90.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) rose 9.8% to $7.04.</li>
<li>Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) surged 9.5% to $136.97.</li>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) gained 8.3% to $1.6250.</li>
<li>Allegiant Travel Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) rose 7.1% to $54.45. Raymond James analyst Savanthi Syth upgraded Allegiant Travel from Outperform to Strong Buy and lowered the price target from $125 to $90.</li>
<li>Studio City International Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 7% to $3.85.</li>
<li>Arcellx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) gained 5.9% to $64.28.</li>
<li>Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) shares rose 4.6% to $64.34.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose 3.8% to $248.24 ahead of quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44605585/how-to-earn-500-a-month-from-conagra-brands-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Movers

Trading Ideas

ACLX

ALGT

ANGO

CGNT

CIEN

COOP

CRWV

GYRE

RDFN

SANA

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Friday.
Shares of Scholastic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) rose sharply during Friday's session following upbeat <a href="https://www.benzinga.com/quote/SCHL/earnings">quarterly earnings</a>.
Scholastic reported quarterly losses of 5 cents per share which beat the analyst consensus estimate of a loss of 78 cents per share. The company reported quarterly sales of $335.400 million which missed the analyst consensus estimate of $347.680 million.
Scholastic shares jumped 12.2% to $21.09 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares jumped 30% to $58.51.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) jumped 23.7% to $9.44.</li>
<li>Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) gained 20.8% to $10.12 after the company reported better-than-expected quarterly financial results.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) shares rose 14% to $0.8021.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) jumped 9% to $6.03 following better-than-expected quarterly results.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) rose 8.2% to $4.4351. Needham analyst Ryan MacDonald reiterated Agilon Health with a Hold rating.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) gained 5.5% to $45.47.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) gained 7.5% to $8.33. Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies from Neutral to Buy and raised the price target from $8 to $9.</li>
<li>Precigen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) shares rose 7% to $1.9250.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>

ADPT

ANNA

CURV

OUST

PGEN

SCHL

Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday

Cytokinetics Said Maintain Expectation For Differentiated Label & Risk Mitigation Profile For Aficamten, If Approved By FDA

High-rolling investors have positioned themselves bearish on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CYTK often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Cytokinetics. This is not a typical pattern.
The sentiment among these major traders is split, with 18% bullish and 72% bearish. Among all the options we identified, there was one put, amounting to $26,400, and 10 calls, totaling $2,209,345.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $60.0 for Cytokinetics over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cytokinetics stands at 6050.25, with a total volume reaching 9,826.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cytokinetics, situated within the strike price corridor from $45.0 to $60.0, throughout the last 30 days.
<h3>Cytokinetics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740775612_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$8.0</td>
<td>$8.3</td>
<td>$60.00</td>
<td>$593.4K</td>
<td>10.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.5</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$50.00</td>
<td>$301.9K</td>
<td>12.9K</td>
<td>503</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.5</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$50.00</td>
<td>$301.6K</td>
<td>12.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.4</td>
<td>$8.0</td>
<td>$8.4</td>
<td>$60.00</td>
<td>$238.5K</td>
<td>10.8K</td>
<td>297</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.1</td>
<td>$5.8</td>
<td>$5.8</td>
<td>$50.00</td>
<td>$233.1K</td>
<td>12.9K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Cytokinetics</h3>
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Following our analysis of the options activities associated with Cytokinetics, we pivot to a closer look at the company's own performance.
<h3>Where Is Cytokinetics Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,337,052, the price of CYTK is down by -6.22%, reaching $44.5.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 68 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cytokinetics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $84.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Morgan Stanley has upgraded their rating to Overweight and adjusted the price target to $67. 
&#x2A; An analyst from Citigroup has revised its rating downward to Buy, adjusting the price target to $86. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $72. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $120. 
&#x2A; Reflecting concerns, an analyst from JMP Securities lowers its rating to Market Outperform with a new price target of $78.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cytokinetics options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Smart Money Is Betting Big In CYTK Options

WIIM

Cytokinetics shares are trading lower after the company reported a Q4 Gaap EPS miss.

Guidance

Cytokinetics Sees FY25 GAAP Operating Expense $670M-$710M

Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.17) by 7.69 percent. This is a 8.7 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $16.927 million which beat the analyst consensus estimate of $1.742 million by 871.94 percent. This is a 912.38 percent increase over sales of $1.672 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Cytokinetics Q4 2024 GAAP EPS $(1.26) Misses $(1.17) Estimate, Sales $16.927M Beat $1.742M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Cytokinetics shares are trading higher amid rumors the company may be acquired. Additionally, Morgan Stanley upgraded the stock from Equal-Weight to Overweight yesterday.

<a href="https://x.com/adamfeuerstein/status/1890472518210752908" title="https://x.com/adamfeuerstein/status/1890472518210752908">https://x.com/adamfeuerstein/status/1890472518210752908</a>

Rumors

Adam Feuerstein Posts On X "Love the idea of $CYTK possibly being acquired, hate rumors on a Friday before a holiday."

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) price target from $190 to $220. Needham analyst Laura Martin maintained a Buy rating. Fidelity National In Reddit formation shares closed at $216.47 on Wednesday. See how other analysts view this stock.</li>
<li>Barclays raised the price target for Mr. Cooper Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NYSE">COOP</a>) from $111 to $130. Barclays analyst Terry Ma maintained an Overweight rating. Mr. Cooper shares closed at $106.71 on Tuesday. See how other analysts view this stock.</li>
<li>Baird slashed The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) price target from $160 to $145. Baird analyst Vikram Kesavabhotla maintained an Outperform rating. Lyft shares closed at $122.23 on Wednesday. See how other analysts view this stock.</li>
<li>HC Wainwright &amp; Co. cut the price target for Cybin Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) from $190 to $150. HC Wainwright &amp; Co. analyst Patrick Trucchio maintained a Buy rating. Cybin shares closed at $9.36 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut the price target for 10x Genomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) from $25 to $12. Leerink Partners analyst Mike Kratky downgraded the stock from Outperform to Market Perform. 10x Genomics shares closed at $12.00 on Wednesday. See how other analysts view this stock.</li>
<li>Morgan Stanley cut Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) price target from $70 to $67. Morgan Stanley analyst Jeffrey Hung upgraded the stock from Equal-Weight to Overweight. Cytokinetics shares settled at $42.18 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho increased MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) price target from $56 to $60. Mizuho analyst Ben Chaiken maintained an Outperform rating. MGM shares closed at $34.37 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) price target from $710 to $900. Canaccord Genuity analyst David Hynes maintained a Buy rating. HubSpot shares closed at $785.50 on Wednesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised the price target for Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) from $65 to $100. Wedbush analyst Nick Setyan maintained an Outperform rating. Dutch Bros shares settled at $64.71 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays increased Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) price target from $56 to $61. Barclays analyst Tim Long maintained an Equal-Weight rating. Cisco shares closed at $62.53 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Pre-Market Outlook

BROS

CSCO

CYBN

HUBS

RDDT

MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Leerink Partners analyst Michael Cherny upgraded the rating for CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) from Market Perform to Outperform and raised the price target from $55 to $75. CVS Health shares closed at $63.22 on Wednesday. <a href="https://www.benzinga.com/quote/CVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Duffy Fischer upgraded DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) from Underweight to Equal-Weight and boosted the price target from $85 to $89. DuPont shares closed at $81.76 on Wednesday. <a href="https://www.benzinga.com/quote/DD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Mohit Bansal upgraded the rating for Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Equal-Weight to Overweight and raised the price target from $130 to $170. Jazz Pharmaceuticals shares closed at $135.44 on Wednesday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Matthew Weston upgraded AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) from Neutral to Buy. AstraZeneca shares closed at $74.43 on Wednesday. <a href="https://www.benzinga.com/quote/AZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Jeffrey Hung upgraded the rating for Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from Equal-Weight to Overweight but lowered the price target from $70 to $67. Cytokinetics shares closed at $42.18 on Wednesday. <a href="https://www.benzinga.com/quote/CYTL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AZN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-1024x574.png" alt="" class="wp-image-780826" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117.png 1088w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Upgrades

JAZZ

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Morgan Stanley analyst Jeffrey Hung upgrades Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from Equal-Weight to Overweight and lowers the price target from $70 to $67.

Morgan Stanley Upgrades Cytokinetics to Overweight, Lowers Price Target to $67

Citigroup analyst David Lebowitz initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy rating and announces Price Target of $86.

Initiation

Citigroup Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $86

JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), noting the company&#8217;s catalyst rich one to two years.
The M&amp;A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot" target="_blank" rel="noreferrer noopener">trial data of&nbsp;aficamten</a> in December 2023. However, last year,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) decided to step back from pursuing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar" target="_blank" rel="noreferrer noopener">the&nbsp;Cytokinetics deal</a>.
Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>
Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) deal and no <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38992589/heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-unce" target="_blank" rel="noreferrer noopener">mergers or acquisitions</a>.
Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.
Stifel has initiated coverage with a Buy rating and a <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $80</a>. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.
Stifel analyst James Condulis writes Cytokinetics&#8217; aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.
As the rollout of Bristol Myers Squibb Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).
While the initial launch is not seen as a negative sign for mavacamten&#8217;s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.
Cytokinetics appears well-positioned to capitalize on Bristol Myers&#8217; groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.
Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.
Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.
Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43131221/halliburton-faces-mixed-q4-with-north-american-weakness-but-global-gains-and-cash-flow-bolster-optimism" target="_blank" rel="noreferrer noopener">Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism</a></li>
</ul>

Analyst Color

Biotech

Health Care

General

AMGN

RPRX

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Press Releases

Cytokinetics to Participate in the Oppenheimer  35th Annual Healthcare Life Sciences Conference

Management

Cytokinetics Names Robert E. Landry to Board of Directors

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Reports Fourth Quarter 2024 Financial Results  and Provides Business Update

Cytokinetics to Participate in March Investor Conferences

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Comments

Cytokinetics

Cytokinetics (CYTK) 옵션

Cytokinetics (NASDAQ:CYTK) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌